WIPR and Brandstock present: Managing Business Risk: How Corporates do Searches
One of the main challenges companies face with their trademarks is managing business risk effectively. In this on-hour webinar, we hear from leading brands about how they minimise risk by developing smarter search strategies to ensure that their trademark portfolios are robust and effective.
RecordedNov 2 201657 mins
Your place is confirmed, we'll send you email reminders
Tom Phillips (WIPR), Lee Curtis (HGF), Rebecca Field (HGF)
It is widely presumed that copyright and design rights are the principal, if not the only, way to protect key aspects of fashion design, such as the look of clothing items.
However, trademark rights, registered and unregistered, are often overlooked from both offensive and defensive points of view. The recent decision of the UK Intellectual Property and Enterprise Court (IPEC) in Freddy v Hugz Clothing has highlighted the possibility of protecting fashion design, in that case a pair of jeans, via the common law right of passing off.
The case highlighted some of the difficulties of enforcing such rights. Registered trademark rights, such as position trademarks, cannot and should not be overlooked when considering protecting elements of fashion design. IP rights owners should not overlook trademark rights, and if you are the subject of a claim such rights should not be dismissed.
Join Lee Curtis and Rebecca Field, HGF, on September 8, 2021 at 4pm BST/ 11am ET for a discussion on Freddy SPA v Hugz Clothing Ltd decision and the use of registered and unregistered trademark rights in the protection of fashion design.
Amendments to Chinese patent law went into effect on June 1, 2021. Some of these amendments have important consequences for life sciences patent practice in China. The most striking change is the establishment of a system for resolving patent disputes in the life sciences.
While similar to the Hatch-Waxman process, the Chinese law also encompasses biologics and traditional Chinese medicines in addition to small-chemical drugs. Amendments are also directed at extensions of patent terms under particular circumstances. This presentation will include a description of the new Chinese system and a comparison to the US system.
Tom Phillips (WIPR), Candida Jaco (RWS), Chris Brothers (RWS)
When the smallest error in translation can result in a patent’s rejection or invalidation, it is important to be mindful of the key steps to successfully translate a patent and the impact it can have if they are not considered.
Join RWS as we present our top five tips to achieve a high-quality patent translation and to learn more about what to look out for when choosing your translation provider, to ensure they are taking the steps necessary to protect your IP.
This session will address the common challenges of translating patents, providing you with techniques and preventive measures you can take to reduce the risks that come with protecting your IP.
- Methods to ensure the patent translation is precise and accurate to maximize protection of your invention
- Solutions to ensure the translated documents are produced on time, on budget and of high quality, every time
- How to overcome patent terminology challenges
- The importance of language and cultural differences
For new inventions, companies generally have the choice between filing a patent application and keeping the invention as a trade secret. Although the general factors for making that decision are well known, there are some nuances when the invention uses artificial intelligence. This presentation provides a simple framework for analyzing inventions that use machine learning, and uses that framework to develop appropriate IP strategies when inventions use AI.
Fred Felman (Appdetex), Sabrina Perelman (Facebook), Tom Phillips (WIPR)
Facebook’s mission is to give people the power to build community and bring the world closer together. Consistent with that mission, Facebook has put in place a suite of measures to help rights holders protect their IP rights on the platform against bad actors who abuse Facebook’s policies.
In this session, we’ll explore the policies, tools and other measures Facebook has in place to combat IP infringement, and the best way for brands to work with Facebook to protect their customers on the platform.
Join Facebook’s Sabrina Perelman and Appdetex’s Fred Felman on July 28 at 11am PST/ 2pm ET/ 7pm BST for a deep dive into Facebook’s IP protection strategy.
Tom Phillips (WIPR), Ryan Keech (BGR), Jason Kelly (BGR), Joachim Steinberg (BGR)
In this timely webinar, three US-based intellectual property litigators will explore post-COVID-19 trends in the protection of “offensive” trademarks in the US.
On one hand, following years of cancellation proceedings, the NFL’s Washington Redskins football team became the Washington Football Team; the Cleveland Indians baseball team ceased use of its Chief Wahoo mascot and announced that it would soon no longer be the Indians; and “Gone With the Wind” was streamed in HBO Max with a disclaimer that the film “denies the horrors of slavery”.
On the other hand, trademark owners—including the producers of certain cannabis products—selling products previously deemed legally and morally questionable saw greater hope that more of their trademarks would qualify for broader US federal trademark protection.
What should we make of these trends? Which trademark owners should be concerned—and who should be pleased? What litigation tools do IP owners have to protect against or take advantage of these trends? Join us to find out.
Patent citations seem like a straightforward concept, but they contain a great deal of complexity. For instance, the expectation of citing patents in a new application varies from jurisdiction to jurisdiction.
There are different types of citations, depending on which office is generating the reports, and different ways in which citations can be used to gain insights on a particular topic.
Along those lines, there are many controversies around what type of citations should be used to generate those insights, and even whether self-citations should ever be used at all.
Join us for an informative webinar about the ins and outs of citations in patent analytics and hear from Tim Campbell (VP, North America, Minesoft), Anna Maria Villa (Patent Expert, IGE /IPI), Christopher Mason (Patent Attorney and Senior Associate, Appleyard Lees), Tony Trippe (Managing Director, PatInformatics), and Jennifer Cessna (Senior Research Scientist, The Hershey Company).
Tom Phillips (WIPR), Jeroen van der Donck (Sonoda & Kobayashi)
At the half-way point of 2021, the world has been engulfed by the COVID-19 pandemic for nearly 18 months. This amount of time is just enough to have a first look at patents and the IP landscape in Japan during this period.
In this webinar, Sonoda & Kobayashi Intellectual Property Law will get you up to speed with 2020’s IP developments in Japan as well as give clarification on the recent trends and shifts observed at the different patent offices.
Particular attention will be devoted to the latest figures of IP filings and litigation in Japan as well as the role of filing by international companies. The World Intellectual Property Organization reported a global increase in patent filing during 2020, but that has not been reflected in Japan, and it appears that the ongoing trend of lower total filings has grown during the pandemic.
The webinar will also address the latest trends with regard to a sub-class of ‘green’ patents: those concerning plastic recycling. Join us as we discuss this topic and other patent trends in the Land of the Rising Sun.
Daniel Shapiro (Red Points), Oli Bolton (Red Points), Tom Phillips (WIPR)
Protecting your brand is essential—it’s how you set yourself apart from the competition. When left unchecked, trademark infringement can quickly lead to financial loss and result in a dilution of your brand value.
IP leaders all around the world are increasingly using trademark monitoring services to ensure their brands remain protected across the internet.
How do they go about protecting their IP using technology? We have put together seven real-world examples of how IP leaders are using brand protection software to gain a competitive edge.
Join our webinar to find out more.
In this webinar you’ll learn:
- Best practices for establishing an efficient and proactive policing and enforcement brand protection programme
- How using a single tool that puts all your IP protection needs under one roof can reduce admin time and costs, and help make strategic decisions in real time
- Seven tangible ways in which IP leaders are using brand protection software to protect their brands
- Metrics and key performance indicators you can track to measure a brand protection software’s success
“Pandemics and Vaccines: The Patent Practitioner View” will be presenting a look at the pandemic history of the 20th and 21st centuries, to see what the world’s biotechnologists were doing to be prepared for fighting them and how that was reflected in patent activities.
Can new vaccines be made before a new and unforecastable pandemic occurs?
What patent activities on new vaccines can be seen around historically known pandemics?
If we analyse their patenting, how continuously do new vaccine developments appear?
These questions will be presented and discussed with viewers by Gorodissky’s patent attorneys who are leaders in the biotechnological arena. A particular focus will be on the situation with patenting new COVID-19 vaccines in Russia as well as on political issues around permitting use of patented vaccines as an exception from exclusive patentee rights in pandemic emergency conditions.
Hazel Ford (Mathys & Squire), Martin MacLean (Mathys & Squire), Peter Scott (WIPR)
European Patent Office (EPO) practice in relation to antibody inventions has developed over the years to take account of progress in the law and advances in technology. The EPO’s approach to patenting antibodies has now been formalised for the first time in the latest edition of the EPO’s Guidelines for Examination (March 2021). In this webinar, Martin MacLean and Hazel Ford of Mathys & Squire will discuss the key issues that are likely to arise when dealing with antibody cases at the EPO, and will review the factors that the EPO will take into account when assessing patentability and when considering what is an appropriate breadth of patent in this technical area.
Fred Felman (Appdetex), Austin Phillips (Facebook), Lisa Widup (Zoom), Dave Caplan (Kilpatrick Townsend), Peter Scott (WIPR)
With the COVID-19 pandemic having kept many of us at home this past year, we’ve witnessed a profound surge in mobile and online commerce and a corresponding increase in scams.
This panel will explore how bad actors’ exploits have evolved over the past year and how IP professionals are battling brand abuse networks and systemic attacks on customers and brands in our evolving digital landscape.
Our expert panel is made up of intellectual property professionals who protect the world’s most influential and fastest-growing brands.
Pawel Piotrowicz (Venner Shipley), Richard Kennedy (Venner Shipley), Peter Thorniley (Venner Shipley)
On March 10, 2021, the Enlarged Board of Appeal of the European Patent Office handed down the long-awaited decision in G 1/19 (Pedestrian Simulation).
What are the key takeaways, and what does the decision mean in practice for applicants and practitioners? Venner Shipley partner Pawel Piotrowicz, who drafted and prosecuted the application and appeared before the Enlarged Board of Appeal, will discuss the key points of the decision, its impact and repercussions for best practice for simulations and other areas such as machine learning and big data.
He will be joined by colleagues Richard Kennedy and Peter Thorniley, who also specialise in computer-implemented inventions.
This will be an interactive webinar with a question and answer session.
After four-and-a-half years of negotiations the dust has now settled on Brexit and its impact on design and trademark protection in the UK and EU—or has it?
This presentation Brexit, trademarks and designs: the end of the beginning? Or just the beginning of the end? on December 16 at 3pm GMT/ 10am ET will provide an overview of what has been agreed on the protection of designs and trademarks in the UK and EU after the UK’s departure from the EU.
The presentation will also deal with the likely ongoing impact of Brexit on UK and EU trademark practice after the end of the transition period on December 31, 2020, providing practical advice on the protection of designs and trademarks and some thoughts on where the UK and EU are likely to diverge in the future in this important area of IP law.
Fred Felman (Appdetex), Russ Pangborn (Seed IP), Tom Phillips (WIPR)
A year unlike any other - as 2020 winds down and the holiday season heats up, we can expect to see even more abuse of intellectual property and brands in digital channels.
Join Russ Pangborn of Seed-IP and Fred Felman of Appdetex in a timely dialogue exploring the hallmarks of abuse in 2020, the current realities of enforcement and how those phenomena will affect brand protection professionals during the always-busy holiday season.
Karthik Subramanian (PatSnap), Shivshankar Umashankar (PatSnap), and Tom Phillips (WIPR)
A recent study from McKinsey claims that 45% of the world’s disease burden could be addressed by biological means. With the increasing number of cancers and other rare diseases, it is no surprise that biotech innovations are on the rise.
To supplement that, advancements in biotechnology such as next-generation sequencing techniques and personalised medicines have made the large-scale development of biological drugs easier and more cost-effective.
The prior art, containing patents for biological gene sequences, and the claims generally include descriptions of gene sequences as a form of protection of DNA, RNA, other nucleotides and proteins.
These patents are always claimed in relation to the sequence upon which the said drug acts. This is mostly with respect to a disease which occurs as a result of sequence mutation, or a disease which the drug is used to treat that acts upon the sequence mentioned in the claim.
Metadata associated to a sequence claimed in a patents has therefore gained more significance than before, for both research and freedom-to-operate perspectives.
In this webinar, we will look closely at how prior art is contributing to drug discovery, and how the trend over the last five years in the prior art landscape has made IP and R&D professionals change the way sequence searching is done.
We also look at how artificial intelligence has helped platforms such as PatSnap Bio shift the approach to sequence searching to the next level, and meet the changing patenting landscape in biological sequencing.
Joel Beevers (Potter Clarkson), Michael Pears (Potter Clarkson), Stephanie Pilkington (Potter Clarkson), Tom Phillips (LSIPR)
Joel Beevers, Michael Pears and Stephanie Pilkington of Potter Clarkson will explore the practical impact of recent CJEU case law in Royalty Pharma (C-650/17) and Teva v Gilead (C-121/17) on what constitutes ‘protection’ of active ingredients by the basic patent in the context of supplementary protection certificates (SPCs); how patent specifications can be optimised for this purpose; and how it can influence patent filing strategies.
They also consider the current state of play for obtaining SPCs for previously authorised active ingredients in view of the recent CJEU judgments in Abraxis (C-443/17) and Santen (C-673/18), and what options remain open to maximise exclusivity.
Tom Leonard (Kilburn & Strode), Alison Care (Kilburn & Strode), Dave Wortley (Kilburn & Strode), Tom Phillips (WIPR)
Antibody Patents: Maximising value in Europe and beyond
Join antibody experts and European Patent Attorneys Tom Leonard, Alison Care and Dave Wortley of Kilburn & Strode for a 60 minute webinar discussion on the latest developments in antibody patenting on Wednesday 5th August 2020 at 4.30pm BST (8.30am West Coast, 11.30am East Coast, 5.30pm Central European Time).
Drawing on both private practice and in-house experience, this in-depth webinar has been specifically curated for those working in the antibody field, including private practice attorneys, in-house counsel and others involved in the development and marketing of antibodies. We will explore best practice for:
· Drafting applications, including how to maximise potential claim scope where possible and what data to include to support your claims
· Patent filing and IP strategies, including when and where to file
· Prosecution of global portfolios, taking into account how different patent offices examine applications relating to antibodies
· The preparation of freedom-to-operate and landscaping opinions to best inform the business or to prepare yourself for third-party due diligence
Jason Yao (Wanhuida IP), Mingming Yang (Wanhuida IP), Tom Phillips (WIPR)
It’s extremely frustrating for brand owners, especially small and medium-sized enterprises, to realise when they plan to launch their products into the China market that their trademarks have been registered by someone else.
This frustration is understandable, and in this webinar, we hear from those who have been vigorously pushing the Chinese legislative authorities to reform the trademark registration regulations, reforms that have recently come to fruition with many positive changes to the Trademark Office, as well as to the Trademark Law.
This webinar will bring you the most up-to-date changes to the trademark registration system and laws in order to deal with bad faith trademark applications. We will also share with you first-hand experiences and strategies in dealing with bad faith registrations, including:
The latest changes to the Trademark Law in China;
How to deal with bad faith trademark registration: opposition; invalidation; cancellation; civil litigations; administrative enforcement actions; and Case study and Q&A.
WIPR and Brandstock present: Managing Business Risk: How Corporates do SearchesJayne McClelland (Syngenta International), Cedric Freymond (Nestlé), Alessia Lorenzini, (Brandstock), Peter Scott (WIPR)[[ webcastStartDate * 1000 | amDateFormat: 'MMM D YYYY h:mm a' ]]56 mins